Overview
RPRX market data
Business OverviewA provider-written description of this company or fund, with its source and observation date.
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
- Source
- massive
- Observed
- Cadence
- Reference data reviewed periodically
- Status
- fresh
Price HistoryDaily closing prices from recorded market data. The latest point represents the most recent completed daily period; prices can move before the next point appears.
RPRX price chart · 1M
- O
- 68.73
- H
- 69.07
- L
- 68.34
- C
- 68.70
- Vol
- 57,941.00
Daily history from Jun 16, 2020
- Source
- US equities market feed
- Observed
- Cadence
- Five-minute page cache; daily and stored hourly bars
- Status
- fresh
Key Stats & PerformanceOpen, range, return and notional-volume facts calculated from daily market bars.
- Open
- $68.73
- Previous Close
- $68.68
- Day High
- $69.07
- Day Low
- $68.34
- 52 Week High
- $70.10
- 52 Week Low
- $36.91
- 7 Day Return
- -1.49%
- 30 Day Return
- +14.35%
- 90 Day Return
- +13.80%
- 1 Year Return
- +77.20%
- Daily Notional Volume
- $4M Latest daily bar volume multiplied by its closing price.
Valuation & ProfitabilityProvider-backed valuation, profitability, and range metrics for the selected company. Display-only; never feeds scores or decisions.
- P/E (TTM)
- 58.25 Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- $1.37 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.37 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- 3.0% Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- 25.7% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $37.31 – $70.37 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $39.1B · P/B 3.44 · P/S 14.95.
Company NewsRecent source-attributed headlines linked to this symbol. Repeated headlines and low-signal items are filtered. Open a headline for its source and context.
10 captured
Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?Zacks Investment Research ·
8-K filing — Royalty Pharma plc (RPRX)SEC EDGAR ·
Royalty Pharma Reports Third Quarter 2026 Financial Results and Raises Full Year GuidanceFiscal.ai ·
Should You Buy Royalty Pharma Stock Before Nov. 4?The Motley Fool ·
Decision & ScoreThis analysis is included with a paid membership. Public prices, charts and source-attributed news remain available without a subscription. Membership does not guarantee an investment outcome.
Trend & Pattern EvidenceThis analysis is included with a paid membership. Public prices, charts and source-attributed news remain available without a subscription. Membership does not guarantee an investment outcome.
Sector Peer RankingThis analysis is included with a paid membership. Public prices, charts and source-attributed news remain available without a subscription. Membership does not guarantee an investment outcome.
AI-selected reference, checked against source evidence · Evidence observed
Frequently Asked QuestionsSource-linked answers to common questions about this asset. Check the evidence observation date and whether the reference was reviewed by a person.
- What business does Royalty Pharma plc operate?
- Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products.
- Which industry is Royalty Pharma plc classified in?
- The SEC company record classifies Royalty Pharma plc under Pharmaceutical Preparations. This filing classification provides industry context alongside the provider's business description.
What to WatchAI-assisted topics for further research about this asset. These are educational prompts, not trading signals or recommendations.
- Business activities described in the company reference
- Original company disclosures and industry classification